Results 1 to 10 of about 4,367 (184)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Drug Design, Development and Therapy, 2018
Isabel M Haugh,1 Allie K Preston,2 Dario N Kivelevitch,1 Alan M Menter1 1Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA; 2Texas A&M Health Science Center College of Medicine, Bryan, TX, USA Abstract: Risankizumab, a ...
Allie Preston, Dario Kivelevitch, Alan Menter   +2 more
exaly   +3 more sources

Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study [PDF]

Therapeutic Advances in Gastroenterology
Background Risankizumab is administered via a new modality, so-called on-body injector (OBI). Objectives To assess the acceptability and the tolerability of OBI-risankizumab therapy, and compare its acceptability with other available modalities in Crohn ...
Anthony Buisson, Karim Gebara MD, Bénédicte Caron, Gilles Boschetti, Cyrielle Gilletta de Saint Joseph, Maria Nachury, Hedia Brixi, Pascal Juillerat, Mélanie Serrero, Lucine Vuitton, Xavier Hebuterne, Ludovic Caillo, Antoine Blain, David Laharie, Laurent Peyrin-Biroulet, Romain Altwegg, Guillaume Le Cosquer, Bruno Pereira, Mathurin Fumery   +18 more
doaj   +2 more sources

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database

Pharmaceutics, 2023
Risankizumab is a selective, humanized immunoglobulin G1 (IgG1) monoclonal anti-body directed against interleukin (IL)-23 protein. The therapeutic indication of risankizumab is moderate-to-severe plaque psoriasis and psoriatic arthritis.
Gioacchino Calapai, Emanuela Esposito, Luigi Cardia   +2 more
exaly   +3 more sources

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial [PDF]

Dermatology and Therapy, 2023
Introduction Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life.
Alexa B. Kimball, Errol P. Prens, Thierry Passeron, Emanual Maverakis, Irina Turchin, Stefan Beeck, Leonidas Drogaris, Ziqian Geng, Tianyu Zhan, Izabella Messina, Falk G. Bechara   +10 more
doaj   +3 more sources

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment

Journal of Immunology Research, 2022
Biological targeted therapy serves as a new alternative treatment for psoriasis due to its minimal side effects. This study is aimed at examining the drug effectiveness and safety of risankizumab and ustekinumab for psoriasis treatment, so as to provide ...
Qianying Yu, Xiaopei Ge, Mingyi Jing, Xiongfei Mi, Jing Guo, Min Xiao, Qing Lei, Mingling Chen   +7 more
doaj   +2 more sources

Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials [PDF]

Frontiers in Immunology
ObjectiveTo compare the efficacy and safety of IL-23 p19 monoclonal antibodies for moderate-to-severe plaque psoriasis.MethodsPubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to 21 February 2026.
Tong Xin, Shanshan Sun, Yihui Liu
doaj   +2 more sources

Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database [PDF]

Frontiers in Pharmacology
BackgroundRisankizumab and guselkumab are two leading interleukin-23 (IL-23) inhibitors for treating immune-mediated inflammatory diseases. While effective, a direct comparison of their real-world safety profiles is lacking.
Shiyi Wang, Yongyi Xu, Hangjuan Lin, Xudong Zhang, Jing Ding, Honggang Jiang, Yihong Fan, Changbo Sun   +7 more
doaj   +2 more sources

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) [PDF]

Dermatology and Therapy
Introduction Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains ...
Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, Francesco Messina, Luca Mastorino, Nicole Macagno, Andrea Carugno, Marco Campoli, Maria Concetta Fargnoli, Viviana Lora, Agnese Rossi, Helena Gioacchini, Luca Potestio, Giovanni Marco D’Agostino, Martina Maurelli, Giampiero Girolomoni, Marco Romanelli, Valentina Dini, Francesco Loconsole, Francesca Satolli, Gianluca Pagnanelli, Claudia Lasagni, Andrea Michelerio, Martina Dragotto, Piergiorgio Malagoli, Nicola Zerbinati, Diego Orsini, Anna Campanati, Matteo Megna, Tommaso Bianchelli, for the Italian Landscape Group, Antonio Costanzo, Simone Ribero, Alessandra Narcisi   +33 more
doaj   +2 more sources

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

Global & Regional Health Technology Assessment, 2021
Purpose: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy.
Paolo Gisondi, Francesco Loconsole, Paola Raimondo, Roberto Ravasio   +3 more
doaj   +1 more source

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab [PDF]

Vestnik Dermatologii i Venerologii, 2022
A review of the literature on the use of the genetically engineered biological drug Skyrizi (INN: risankizumab) for the treatment of psoriasis in patients is presented. The problem of high dissatisfaction of patients with the available means (methods) of
Andrey L. Bakulev, Larisa S. Kruglova
doaj   +1 more source